Toggle light / dark theme

MIT solved a century-old differential equation to break ‘liquid’ AI’s computational bottleneck

Last year, MIT developed an AI/ML algorithm capable of learning and adapting to new information while on the job, not just during its initial training phase. These “liquid” neural networks (in the Bruce Lee sense) literally play 4D chess — their models requiring time-series data to operate — which makes them ideal for use in time-sensitive tasks like pacemaker monitoring, weather forecasting, investment forecasting, or autonomous vehicle navigation. But, the problem is that data throughput has become a bottleneck, and scaling these systems has become prohibitively expensive, computationally speaking.

On Tuesday, MIT researchers announced that they have devised a solution to that restriction, not by widening the data pipeline but by solving a differential equation that has stumped mathematicians since 1907. Specifically, the team solved, “the differential equation behind the interaction of two neurons through synapses… to unlock a new type of fast and efficient artificial intelligence algorithms.”

“The new machine learning models we call ‘CfC’s’ [closed-form Continuous-time] replace the differential equation defining the computation of the neuron with a closed form approximation, preserving the beautiful properties of liquid networks without the need for numerical integration,” MIT professor and CSAIL Director Daniela Rus said in a Tuesday press statement. “CfC models are causal, compact, explainable, and efficient to train and predict. They open the way to trustworthy machine learning for safety-critical applications.”

Two Fathers One Egg

What will it take for a same-sex couple—two males or two females—to be able to produce a biological child by combining their genomes in the same way that male-female couples do? Just to be clear, we’re not talking about adopting. Nor do we mean one mate fertilizes a donor egg or is fertilized with donated sperm. Those things have long existed. We mean you take two women or two men and make a baby.

And they’ve already done it with two male mice.

Transforming bacterial cells into living artificial neural circuits

Bringing together concepts from electrical engineering and bioengineering tools, Technion and MIT scientists collaborated to produce cells engineered to compute sophisticated functions— biocomputers of sorts.

Graduate students and researchers from Technion—Israel Institute of Technology Professor Ramez Daniel’s Laboratory for Synthetic Biology & Bioelectronics worked together with Professor Ron Weiss from the Massachusetts Institute of Technology to create genetic “devices” designed to perform computations like artificial neural circuits. Their results were recently published in Nature Communications.

The was inserted into the bacterial cell in the form of a plasmid: a relatively short DNA molecule that remains separate from the bacteria’s “natural” genome. Plasmids also exist in nature, and serve various functions. The research group designed the plasmid’s genetic sequence to function as a simple computer, or more specifically, a simple artificial neural network. This was done by means of several genes on the plasmid regulating each other’s activation and deactivation according to outside stimuli.

The Future of Consciousness — Andrés Gómez Emilsson

Synopsis: In this talk we articulate a positive vision of the future that is both viable given what we know, and also utterly radical in its implications. We introduce two key insights that, when taken together, synergize in powerful ways. Namely, (a) the long-tails of pleasure and pain, and (b) the correlation between wellbeing, productivity, and intelligence. This informs us how to distribute resources if we want to maximize wellbeing. Given the weight of the extremes, it is important to take them into account. But because of the causal significance of more typical hedonic ranges, engineering our baseline is a key consideration. This makes it natural to break down the task of paradise engineering into three components:

Avoid negative extremes.
increase hedonic baseline, and.
achieve new heights of experience.

With regards to : the future of consciousness is anodyne. It lacks extreme suffering in any of its guises. We will see how, if we aim right, a significant proportion of extreme suffering can be prevented with pragmatic technologies already available. Even just applying what we know today would be as significant for the reduction of suffering as the advent of anesthesia was in the context of surgery.

On : the future of consciousness is engaging. From novelty generation to Buddhist annealing, baseline-enhancing interventions will change the way we think of life. It is not only about making everyday fun, but also the economics of it.

And : the future of consciousness is ecstatic. A science of ecstasy will allow us to safely and reliably sample from a wide range of time-tested ultra-blissful peak experiences. A common cause with other sentient beings, and indeed with the interests of consciousness at large, can be forged in the knowledge of such deep experiences.

They give you a genuine, non-sentimental, reason to live. Together, action on these three levels can significantly advance the cause of eliminating suffering and engineering paradise. And our assessment is: there is a lot of low-hanging fruit in this space. Let’s pick it up!

The world’s population has reached 8 billion and counting

A result of the gradual increase in human lifespan and high and persistent levels of fertility in some countries.

The world’s population hit eight billion today, November 15, and this is a “milestone in human development,” according to a statement by the United Nations (UN).

This unprecedented growth is due to the gradual increase in human lifespan owing to improvements in public health, nutrition, personal hygiene, and medicine.


Dmytro Varavin/iStock.

Considering the fact that the last time the global population notched seven billion was in 2011, the world population increased by one billion in the last 11 years. This raises concerns about overpopulation, which is directly linked to climate change.

Dr. Michael Hufford, PhD — Advancing Novel Therapeutic Interventions For Unmet Medical Needs

Advancing Novel Therapeutic Interventions For Unmet Medical Needs — Dr. Michael Hufford, Ph.D., Co-Founder and CEO, LyGenesis; Interim CEO, Morphoceuticals; Scientific Advisor, Juvenescence.


Dr. Michael Hufford, Ph.D. is the Co-Founder and the Chief Executive Officer of LyGenesis (https://www.lygenesis.com/), a clinical-stage cell therapy company that transforms patient’s lymph nodes into bioreactors capable of growing functioning ectopic organs. He also serves as the Interim CEO of Morphoceuticals (https://www.morphoceuticals.com/) a company focused on modifying electric potentials in cells and tissues for a variety of applications in regenerative medicine, from improving amputation stump health and limb regeneration, to organogenesis, to creating a bioelectric atlas where numerous disease indications may be corrected.

Dr. Hufford also serves as a scientific advisor to Juvenescence (https://juvlabs.com/) a biotech holding company that develops therapies and products to modify aging and help people live longer.

An entrepreneur and drug developer, Dr. Hufford has over 20 years of experience in the development and FDA regulatory approval of small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has designed and executed clinical trials and drug development programs across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatric and oncology indications. His experience in-and out-licensing pre-clinical and clinical stage assets, executing corporate partnering deals, and in investor relations, has helped him to raise public, private, and angel-back financing for his companies. His philanthropic work includes co-founding and serving as the CEO of Harm Reduction Therapeutics, Inc. (https://www.harmreductiontherapeutics.org/), a nonprofit pharmaceutical company developing low-cost over-the-counter intra-nasal naloxone in the US to help prevent opioid overdose deaths.

Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master’s and doctoral degrees in Clinical Psychology from the University of Pittsburgh, before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is an award-winning lecturer, and the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.

/* */